Skip to content
Menu

Cantor Fitzgerald Reiterates Overweight on IRulya Therapeutics, Maintains $70 Price Target

Benzinga Newsdesk 11 hours ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates IRulya Therapeutics (NASDAQ:IRLA) with a Overweight and maintains $70 price target.

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates IRulya Therapeutics (NASDAQ:IRLA) with a Overweight and maintains $70 price target.

Read at benzinga.com